An interventional study of Bilateral Posterior Superior Plane Block and Bilateral Transversus Thoracic Plane in Postoperative Pain Following Coronary Artery Bypass Grafting (CABG), sponsored by Ain Shams University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Ain Shams University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 364 studies testing bupivacaine in Pain, Postoperative — 57 open to participants now, 60 under way, 5 of them phase 3. Bupivacaine · Pain, Postoperative.
Among the 364 studies testing bupivacaine in Pain, Postoperative, this one is the 97th largest by enrollment, is one of 22 that started in 2026, is one of 111 with no phase, and was the 347th registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →57 of the 364 studies testing bupivacaine in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18+
Hitit University · Sites in Turkey
Ages 18–75
Wah Medical college , POF hospital · Sites in Pakistan
Ages 18–60
Tianjin First Central Hospital · Sites in China
Ages 18–80
Erkan Gol · Sites in Turkey
Ages 18+ · Women only
By country, each count listing its studies:
Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
364 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 57 · Phase 3 53 · Phase 4 133
First in 2004; this study’s year is marked. 22 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is above the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 70 across the 364 interventional studies. Of the 258 that completed or were terminated, 106 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 364 have an industry lead sponsor. The 10 most frequent:
Ain Shams University is the lead sponsor of 1,958 studies on the registry; 432 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
102 studies in Pain, Postoperative by Ain Shams University: 24 open now, 28 under way, 2 of them phase 3. Of 63 finished, 3 (5%) have results posted.
Among the 102 studies in Pain, Postoperative by Ain Shams University, this one is the 20th largest by enrollment of the 100 interventional ones that give a count, is one of 9 that started in 2026, is one of 62 with no phase, and was the 94th registered.
Ain Shams University’s Pain, Postoperative studies by the year they started, since 2013.
22 of the studies testing bupivacaine in Pain, Postoperative that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06350981Phase 3Foundation for Orthopaedic Research and EducationAnalgesic Requirement for Post-Operative Pain Control in TLIP Interbody Fusion | 2027-01-01 |
| NCT06077422Phase 3Rutgers, The State University of New JerseyExparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain | 2027-01-11 |
| NCT07650760Wah Medical college , POF hospitalComparison of Intraperitoneal Bupivacaine and Saline Irrigation for Pain Relief After Laparoscopic Cholecystectomy | 2026-12 |
| NCT03737292Milton S. Hershey Medical CenterLiposomal Bupivacaine Versus Plain Bupivacaine After Intercostal Injections For Pain Management After Thoracoscopy | 2026-12 |
| NCT02381353Mayo ClinicExparel Injection for Postoperative Orbital Pain | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 364 studies testing bupivacaine in Pain, Postoperative, from their registry updates:
Among Ain Shams University’s 102 in Pain, Postoperative:
This tab as a report to print or save as PDF → With an account.
After heart bypass surgery (coronary artery bypass grafting, CABG), the breastbone is divided to reach the heart, which causes significant pain. Pain can make deep breathing and coughing difficult and may slow recovery. Strong pain medicines called opioids are the usual treatment, but they can cause side effects such as drowsiness, slowed breathing, nausea, vomiting, and confusion.
This study tested whether two nerve blocks given together can reduce the need for opioids after bypass surgery. A nerve block is an injection of local anesthetic, guided by ultrasound, that numbs a specific area of the body. The two blocks are the serratus posterior superior plane (SPSP) block, which numbs the upper side and back of the chest wall, and the transversus thoracic plane (TTP) block, which numbs the front of the chest next to the breastbone. Both were placed on each side of the chest after the patient was asleep under general anesthesia and before surgery began.
Adults aged 18 to 75 having planned (non-emergency) bypass surgery were randomly assigned, by chance, to one of two groups. One group received both blocks plus standard pain medicines. The other group received standard pain medicines alone. Patients did not know which group they were in, and the staff who measured outcomes were also unaware of group assignment.
The main question was how much opioid medicine patients needed in the first 48 hours after the breathing tube was removed. Other measures included pain scores at rest and with movement, time until first rescue pain medicine, time to breathing-tube removal, oxygen levels, length of ICU and hospital stay, time to first getting out of bed, patient satisfaction, and side effects such as complications from the blocks or from opioids.
The results may help doctors decide whether combining these two blocks is a useful way to control pain and reduce opioid use after heart bypass surgery.
Rationale. Opioid-centered analgesia after CABG delays recovery, and thoracic epidural analgesia is generally avoided in patients who are fully anticoagulated. The SPSP block covers the lateral and posterior chest wall, and the TTP block covers the anterior parasternal region. Their combined use had not been evaluated in a prospective randomized trial in cardiac surgery.
Hypothesis. Combined bilateral SPSP and TTP blocks lower 48-hour postoperative opioid consumption compared with standardized systemic analgesia alone in elective isolated CABG.
Design. Single-center, prospective, parallel-group, superiority randomized controlled trial with 1:1 allocation. Randomization used a computer-generated permuted block sequence (block sizes 4 and 6) prepared by a statistician not involved in care. Allocation was concealed with sequentially numbered, opaque, sealed envelopes, opened after induction of anesthesia.
Blinding. Patients (blocks were placed under general anesthesia) and all outcome assessors were blinded. The performing anesthesiologist could not be blinded and took no part in postoperative care, outcome assessment, data collection or analysis. Study syringes were labeled "Study Injection". Local wound infiltration was prohibited in both groups, and compliance was checked against anesthesia and nursing records. No sham procedure was used.
Standardization. Intraoperative and postoperative analgesia followed one protocol in both groups, including rescue criteria and conversion of all opioids to morphine milligram equivalents (MME). Intraoperative opioid doses were recorded separately and excluded from the primary outcome.
Block success. Assessed once, after extubation, by a blinded assessor using cold and pinprick testing over the expected dermatomes. Success rates were reported descriptively and defined the per-protocol population.
Safety monitoring. Resuscitation equipment and lipid emulsion were available at the bedside, with continuous ECG, arterial pressure, and SpO₂ monitoring. Block sites were inspected at 30 min, 6 h, and 24 h, and lung ultrasound was used for new desaturation or respiratory distress.
Statistical analysis. Intention-to-treat was primary. The primary outcome was compared with the Mann-Whitney U test (Hodges-Lehmann estimate with 95% CI), with ANCOVA adjusted for intraoperative opioid consumption as a sensitivity analysis. Secondary outcomes were prespecified, not powered, and considered hypothesis-generating.
Sample size. The target of 100 (50 per group) was set before enrollment, exceeding the originally calculated 88, to allow for block failure and to improve precision of secondary estimates.
Reporting. CONSORT 2025.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive bilateral ultrasound-guided serratus posterior superior (SPSP) plane block and bilateral transversus thoracic plane (TTP) block.
Procedure: Bilateral Posterior Superior Plane Block · Procedure: Bilateral Transversus Thoracic Plane · Drug: Conventional Systemic Analgesia · Drug: Bupivacaine 0.25%
Participants receive standardized multimodal systemic analgesia alone without any regional anesthesia blocks.
Drug: Conventional Systemic Analgesia
With the patient in slight lateral tilt (15-20°), the trapezius (superficial), rhomboid major/minor, and the fascial plane deep to the rhomboids overlying the serratus posterior superior muscle at T2 to T5 were identified. Using a 22-gauge, 50-80 mm echogenic needle (Stimuplex Ultra 360, B. Braun) and an in-plane lateral-to-medial approach, after negative aspiration and a 1 mL test dose, 15 mL of 0.25% bupivacaine per side was deposited incrementally, confirming fascial spread under continuous ultrasound guidance. The procedure was repeated on the contralateral side.
With the patient supine, a parasternal short-axis scan was performed at the second-fourth intercostal space level. The pectoralis major (superficial), internal intercostal muscle, and transversus thoracic muscle (deep) were identified. Using a 22-gauge, 50-80 mm echogenic block needle (Stimuplex Ultra 360, B. Braun) and an in-plane approach, after negative aspiration and a 1 mL test dose, 15 mL of 0.25% bupivacaine per side was deposited in 3-5 mL increments with intermittent aspiration, confirming fascial spread (downward displacement of the pleura). The procedure was repeated on the contralateral side.
Standardized multimodal systemic analgesia regimen administered to both groups. Intraoperative: fentanyl 5-10 mcg/kg at induction with supplemental 1-2 mcg/kg boluses as needed. Postoperative: paracetamol 1 g every 6 hours from ICU arrival. A continuous intravenous fentanyl infusion commenced at 0.5 μg/kg/h once the patient emerged from anesthesia and NRS assessment became feasible. The fentanyl infusion weaned by 25% every hour prior to planned extubation and discontinued at extubation. Intravenous morphine was administered in incremental doses of 2-3 mg every 10 minutes when the NRS score was ≥4, with repeated doses until satisfactory analgesia (NRS ≤3) was achieved. Additional rescue doses of 1-2 mg were provided as required based on subsequent pain assessments.
Local anesthetic administered for regional blocks; total dose up to 2.5 mg/kg (maximum 150 mg for patients ≥65 kg, adjusted for lower weights)
Accumulated from time of tracheal extubation through 48 hours post-extubation
Cumulative intravenous morphine milligram equivalents (MME) from tracheal extubation (time 0) to 48 hours post-extubation. All opioid doses administered during this period will be recorded and converted to IV MME using standardized conversion ratios: fentanyl 1 mcg IV = 0.1 mg IV morphine equivalent; hydromorphone 1 mg IV = 5 mg IV morphine equivalent; oxycodone 1 mg oral = 1.5 mg IV morphine equivalent; tramadol 1 mg IV = 0.1 mg IV morphine equivalent. The primary analysis will compare total 48-hour MME between the combined SPSP + TTP block group and the conventional analgesia group.
Time frame: rom time of tracheal extubation until administration of first rescue IV morphine dose for NRS ≥ 4, assessed up to 48 hours post-extubation
NRS pain score at rest
Numeric Rating Scale (0 = no pain, 10 = worst imaginable pain) assessed at rest at extubation (0 h), 6 h, 12 h, 24 h, and 48 h post-extubation.
Time frame: Assessed at extubation (0 h), 6 hours, 12 hours, 24 hours, and 48 hours post-extubation
NRS pain score on movement/coughing
Numeric Rating Scale (0-10) assessed during deep inspiration, coughing, or turning in bed at 0 h, 6 h, 12 h, 24 h, and 48 h post-extubation.
Time frame: Assessed at extubation (0 h), 6 hours, 12 hours, 24 hours, and 48 hours post-extubation
Time to first rescue analgesic
Minutes from tracheal extubation to first administration of rescue opioid for Numeric Rating Scale ≥ 4 at rest or on patient demand. Rescue protocol: IV morphine 2-3 mg every 5-10 minutes titrated to NRS ≤ 3. Recorded by blinded ICU nursing staff.
Time frame: From time of tracheal extubation until administration of first rescue IV morphine dose for NRS ≥ 4, assessed up to 48 hours post-extubation
Time to tracheal extubation
Minutes from end of surgery (skin closure) to successful tracheal extubation in the intensive care unit. Successful extubation defined as removal of endotracheal tube with spontaneous breathing maintained for at least 30 minutes without reintubation.
Time frame: From end of surgery (skin closure) until successful removal of endotracheal tube and spontaneous breathing without ventilatory support, assessed up to 48 hours
Arterial oxygenation (PaO₂/FiO₂ ratio)
Arterial oxygen tension to inspired oxygen fraction ratio measured at 6 hours and 24 hours post-extubation
Time frame: Assessed at 6 hours and 24 hours post-extubation
Incidence of atelectasis
incidence of atelectasis (radiographic confirmation)
Time frame: From time of tracheal extubation until hospital discharge or postoperative day 30, whichever occurs first
Incentive spirometry volume
Volume achieved with incentive spirometry in millilitres at 24 and 48 hours post-extubation. Assessed by a blinded physiotherapist or nursing staff using standardized technique.
Time frame: Assessed at 24 hours and 48 hours post-extubation
Pulmonary complications
Incidence of atelectasis (radiographic confirmation), pneumonia (clinical and radiographic criteria per CDC definitions), or reintubation occurring during the hospital stay. Composite binary outcome.
Time frame: From time of tracheal extubation until hospital discharge or postoperative day 30, whichever occurs first
Intensive care unit length of stay
Hours from intensive care unit admission to ICU discharge to the ward. Discharge criteria per institutional protocol: hemodynamic stability without vasopressors, adequate oxygenation on room air or low-flow oxygen, and no active arrhythmias requiring intervention.
Time frame: From ICU admission until ICU discharge, assessed up to 7 days postoperatively
Hospital length of stay
Days from surgery (admission) to hospital discharge. Discharge criteria per institutional protocol: ambulatory, pain controlled on oral analgesics, wound healing satisfactory, and no active medical issues requiring inpatient management.
Time frame: From date of surgery until date of hospital discharge, assessed up to 30 days postoperatively
Patient satisfaction with pain management
Likert scale 1-5 (1 = very dissatisfied, 2 = dissatisfied, 3 = neutral, 4 = satisfied, 5 = very satisfied) assessing overall satisfaction with postoperative pain management at 48 hours post-extubation. Completed by patient with blinded assessor assistance if needed.
Time frame: Assessed at 48 hours post-extubation using a 5-point Likert scale
Time to first ambulation
Hours from tracheal extubation to first assisted ambulation greater than 10 metres. Ambulation is defined as standing and walking with or without assistance. Recorded by blinded ICU or ward physiotherapy staff.
Time frame: From time of tracheal extubation until first documented assisted or unassisted ambulation, assessed up to 7 days postoperatively or until hospital discharge, whichever occurs first
Block-related complications
Incidence of pneumothorax (symptomatic or radiographic), local hematoma at the injection site, infection (erythema, warmth, or purulent discharge), or nerve injury in the intervention group. Monitored by clinical examination, chest auscultation, and imaging as indicated.
Time frame: From performance of regional blocks until hospital discharge or postoperative day 30, whichever occurs first.
Local anesthetic systemic toxicity
Signs and symptoms of LAST: CNS manifestations including tinnitus, circumoral numbness, metallic taste, agitation, dizziness, or seizure; cardiovascular manifestations including arrhythmia, bradycardia, ventricular tachycardia, hypotension, or cardiac arrest.
Time frame: From initiation of regional block injection until 24 hours post-block.
Opioid-related adverse events
Respiratory depression requiring naloxone administration; severe nausea or vomiting requiring antiemetic intervention; ileus, defined as absence of bowel sounds greater than 48 hours; urinary retention requiring catheterization, or postoperative delirium.
Time frame: From time of tracheal extubation through hospital discharge or postoperative day 30, whichever occurs first.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual participant data underlying published results will be shared with qualified researchers upon reasonable request to the principal investigator, subject to approval by the Ain Shams University IRB and execution of a data use agreement.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Access criteria: Data will be available beginning 9 months after primary publication and ending 36 months thereafter.
Ran from Jul 2026 to primary completion in Sep 2026, 2 months.
Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 2 months is below that.
Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Dec 2026 → Sep 2026 and completion Jan 2027 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bupivacaine